February 28, 2015 8:05 PM ET

Pharmaceuticals

Company Overview of Zoetis Inc.

Company Overview

Zoetis Inc. is engaged in the discovery, development, manufacture, and commercialization of animal health medicines and vaccines for livestock and companion animals worldwide. It operates through four segments: United States, Europe/Africa/Middle East, Canada/Latin America, and Asia/Pacific. The company offers anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; vaccines that are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; and parasiticides that prevent or eliminate external and internal parasites, such as fleas, ticks, and worms. It also provides medicated f...

100 Campus Drive

Florham Park, NJ 07932

United States

Founded in 1952

10,000 Employees

Phone:

973-822-7000

Key Executives for Zoetis Inc.

Chief Executive Officer and Director
Age: 63
Total Annual Compensation: $825.0K
Group President and Executive Vice President
Age: 42
Total Annual Compensation: $605.0K
Executive Vice President and President of U.S. Operations
Age: 47
Total Annual Compensation: $400.0K
President of Research & Development and Executive Vice President
Age: 53
Total Annual Compensation: $400.0K
Compensation as of Fiscal Year 2013.

Zoetis Inc. Key Developments

Zoetis Inc. Declares Dividend for the Second Quarter of 2015, Payable on June 2, 2015

The Board of Directors of Zoetis Inc. has declared a second quarter 2015 dividend payable to holders of the company's common stock of $0.083 per share. The dividend is to be paid on Tuesday, June 2, 2015, to holders of record on April 9, 2015.

Zoetis Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Full year Ended December 31, 2014; Revises Earnings Guidance for 2015

Zoetis Inc. announced unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported revenue of $1,320 million against $1,254 million a year ago. Income before provision for taxes on income was $155 million against $126 million a year ago. Net income attributable to the company was $126 million against $105 million a year ago. Diluted earnings per share were $0.25 against $0.21 a year ago. Non-GAAP income before provision for taxes on income was $249 million against $252 million a year ago. Non-GAAP net income attributable to the company was $203 million against $180 million a year ago. Non-GAAP diluted earnings per common share attributable to the company were $0.40 against $0.36 a year ago. For the year, the company reported revenue of $4,785 million against $4,561 million a year ago. Income before provision for taxes on income was $820 million against $690 million a year ago. Net income attributable to the company was $583 million against $504 million a year ago. Diluted earnings per share were $1.16 against $1.01 a year ago. Non-GAAP income before provision for taxes on income was $1,084 million against $1,000 million a year ago. Non-GAAP net income attributable to the company was $790 million against $709 million a year ago. Non-GAAP diluted earnings per common share attributable to the company were $1.57 against $1.42 a year ago. For 2015, the company expects revenue to be in the range of $4,800 million to $4,900 million against $4,850 million to $4,950 million as previously expected. The company expects operational growth to be in the range of 6.5% to 8.5%. Effective tax rate on adjusted income approximately 29%. The company expects adjusted diluted EPS to be in the range of $1.61 to $1.68 and adjusted net income to be in the range of $810 million to $845 million. The company expects reported diluted EPS to be in the range of $1.32 to $1.39 against $1.36 to $1.43 as previously expected. The company expects reported net income attributable to the company to be in the range of $665 million to $700 million. Adjusted interest expense and other (income)/deductions of approximately $110 million.

Zoetis Inc. Appoints William Doyle as Director, to Serve as Member of the Corporate Governance Committee of the Board

On February 3, 2015, the Board of Directors of Zoetis Inc. appointed Mr. William Doyle to serve as a director of the company with a term expiring at the 2016 Annual Meeting, with such appointment to be effective immediately. The Board also appointed Mr. Doyle to serve as a member of the Corporate Governance Committee of the Board. In connection with the appointment of Mr. Doyle, the size of the Board of Directors of the company was increased from nine to ten members.

Similar Private Companies By Industry

Company Name Region
Purdue Pharma L.P. United States
Sigma-Tau Pharmaceuticals, Inc. United States
GPS Group LLC United States
Selexys Pharmaceuticals Corporation United States
Alba Therapeutics Corporation United States

Recent Private Companies Transactions

Type
Date
Target
Buyback
November 18, 2014
--
Merger/Acquisition
November 17, 2014
Abbott Animal Health, Animal Health Assets
Merger/Acquisition
November 11, 2014
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Zoetis Inc., please visit www.zoetis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.